In the cycle of research meetings where medicine tests its hopes against patients' lives, AstraZeneca brought forward late-stage data on an experimental stomach cancer drug at the European Society for Medical Oncology gathering. The drug, an antibody-drug conjugate, extended overall survival, the measure most people facing this disease care about most, even as its phase 3 trial fell short on progression-free survival, a gauge of how long disease stays in check. The company argues that the survival gain outweighs that miss and that the evidence is strong enough for regulators to consider, a jud
AstraZeneca's Stomach Cancer Drug Extends Survival at ESMO, Though It Missed a Progression Endpoint
A survival gain on one measure, a miss on another
In the cycle of research meetings where medicine tests its hopes against patients' lives, AstraZeneca brought forward late-stage data on an experimental stomach cancer drug at the European Society for Medical Oncology gathering. The drug, an antibody-drug conjugate, extended overall survival, the measure most people facing this disease care about most, even as its phase 3 trial fell short on progression-free survival, a gauge of how long disease stays in check. The company argues that the survival gain outweighs that miss and that the evidence is strong enough for regulators to consider, a judgment that rests with them and has not yet been made. The result sits within a wider company push toward targeted cancer treatments, and whether it holds under full regulatory scrutiny is the question still unanswered.
At the European Society for Medical Oncology meeting, AstraZeneca presented late-stage data on an experimental stomach cancer drug, an antibody-drug conjugate tested in a phase 3 trial. The headline finding is that the drug extended overall survival, the outcome patients weigh most heavily.
The trial was not a clean sweep. It missed its progression-free survival endpoint, which measures how long disease stays under control. Bloomberg's headline went so far as to say survival had doubled, but the reporting available here does not include the figures needed to test that claim.
An AstraZeneca executive has argued that the miss does not undermine the case, and that the data are robust enough to take to regulators. That is the company's view of how the evidence should be weighed, not a regulatory decision. The presentation also sits within a broader company effort to build a portfolio of targeted cancer therapies.
What comes next is regulatory: filings, and a full review of whether the survival benefit holds and how the missed endpoint is treated.
The headlines gathered around a single set of trial results this week. At the European Society for Medical Oncology meeting, ESMO, AstraZeneca presented late-stage data on an experimental stomach cancer drug, and the outlets covering it framed the result in different ways. Reuters reported that the drug extended overall survival. Bloomberg went further, with a headline saying the drug doubled survival time.
The drug is an antibody-drug conjugate, or ADC, and the data come from a phase 3 trial. The trial did not clear every bar it set for itself. It missed its progression-free survival endpoint, the measure of how long patients live without their disease getting worse. That miss sits beside the overall survival finding, and the two results point in different directions.
Fierce Biotech reported that an AstraZeneca executive pushed back on the idea that the miss undermines the case. The executive described the phase 3 ADC data as robust enough to take to regulators despite the progression-free survival shortfall. That is the company's position, and it is a position about how regulators will weigh the evidence, not a ruling by them.
The stomach cancer data were one part of a larger presentation. STAT described ESMO as a showcase for AstraZeneca's cancer pursuits, and The Wall Street Journal reported that the company is preparing a new portfolio of targeted cancer therapies. The stomach cancer drug is therefore part of a broader push into targeted treatments, not a stand-alone bet.
The coverage available here is headline-level, and several specifics are not in it. The names of the drug and the trial, the number of patients enrolled, the actual survival figures in months, and any safety findings are absent from this material. Bloomberg's phrase about doubling survival time is a characterization in a headline, and without the underlying numbers it is hard to say what was doubled, or compared against what.
What the reporting does establish is the shape of the result: a survival benefit on the endpoint that matters most to patients, a miss on a secondary-looking measure of disease control, and a company arguing that the first outweighs the second. Overall survival is generally the harder and more persuasive endpoint, but how regulators treat a split result is a judgment still to come.
The next steps are regulatory. Watch for AstraZeneca to file the data with regulators, and for whether the survival gains hold up under full review, including the complete dataset behind the ESMO presentation and how the progression-free survival miss is handled.
Citations marquantes
The phase 3 ADC data are robust enough for regulators despite the progression-free survival miss (paraphrased).— AstraZeneca executive, as reported by Fierce Biotech
Envie de l'histoire complète ?
Lire l'original sur Google News ↗
Health & Medicine